bisoprolol   Click here for help

GtoPdb Ligand ID: 7129

Synonyms: CL-297939 | EMD-33512 | Zebeta®
Approved drug
bisoprolol is an approved drug (FDA (1992))
Compound class: Synthetic organic
Comment: Bisoprolol is a β-blocker, selective for β1-adrenoceptors in cardiac tissue. The S(-) enantiomer is believed to account for most of its β-blocking activity.
Marketed formulations may contain bisoprolol fumarate (PubChem CID 6917733).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 59.95
Molecular weight 325.23
XLogP 2.16
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(COc1ccc(cc1)COCCOC(C)C)CNC(C)C
Isomeric SMILES OC(COc1ccc(cc1)COCCOC(C)C)CNC(C)C
InChI InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
InChI Key VHYCDWMUTMEGQY-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor.
J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
5. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
FASEB J, 31 (7): 3150-3166. [PMID:28400472]
6. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
FASEB J, 25 (12): 4486-97. [PMID:21865315]
7. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
8. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]
9. Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. (2023)
The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor.
Mol Pharmacol, 103 (2): 89-99. [PMID:36351797]
10. Smith C, Teitler M. (1999)
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors.
Cardiovasc Drugs Ther, 13 (2): 123-6. [PMID:10372227]
11. Sykes DA, Jiménez-Rosés M, Reilly J, Fairhurst RA, Charlton SJ, Veprintsev DB. (2022)
Exploring the kinetic selectivity of drugs targeting the β1 -adrenoceptor.
Pharmacol Res Perspect, 10 (4): e00978. [PMID:35762357]